Navigation Links
Amarantus BioScience to Present at the 15th Annual BIO CEO & Investor Conference
Date:2/8/2013

SUNNYVALE, Calif., Feb. 8, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Gerald E. Commissiong , President and Chief Executive Officer will present a corporate update  at the 15th Annual BIO CEO & Investor Conference hosted by the Biotechnology Industry Organization (BIO). The presentation will take place on Monday, February 11, 2013 at the Waldorf Astoria in New York, NY.

The presentation will be webcast and available in the IR Calendar section of the Company's website at www.amarantus.com

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.

CORPORATE CONTACTS

Amarantus Bioscience, Inc. 
ir@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
(408) 737-2734 x109
remy@irsense.com


'/>"/>
SOURCE Amarantus BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with ... strains genetically engineered to express human antibodies. The partnership will use GigaGen technology ...
(Date:2/28/2017)... , Feb. 28, 2017  ITL Limited ... company, supplier and strategic partner that provides innovative ... individual health management, formally announces its rebrand to ... name change is part of the Company,s unified ... launch of an integrated corporate website, ITLHealthGroup.com ...
(Date:2/28/2017)... and NEW YORK , February ... License Application accepted by the FDA for avelumab  ... disease has metastasized   ... Germany , in the US and ... US Food and Drug Administration (FDA) has accepted for Priority ...
(Date:2/27/2017)... -- A Europe-wide survey of institutes conducted by the ... their research treat them with due care. The survey polled a ... the results indicates that there is a strong commitment among animal ... the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the 3Rs? ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
Breaking Biology News(10 mins):